Top Markets
Coin of the day
Healios K.K. Healios K.K.

Healios K.K.

4593
Rank in Stocks #17173
Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011,... Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.
Share Price
$1.89
Market Cap
$254.55M
Change (1 day)
-2.03%
Change (1 year)
-48.53%
Country
JP
Trade Healios K.K. (4593)

Category

Stock price history for Healios K.K. (4593)
Highest end of day price: $1.91 on 2026-09-01

Lowest end of day price: $12.24 on 2015-06-01
Stock price history of Healios K.K. from 2015 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) 10.25%
2025 88.62%
2024 -2.29%
2023 -42.34%
2022 -81.62%
2021 -40.66%
2020 45.21%
2019 -16.02%
2018 2.08%
2017 -12.10%
2016 85.34%
2015 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$548.15 36.70%
US
$1.03K 45.33%
NL
$153.87 536.09%
US
$122.21 -10.03%
AU
$757.71 8.20%
CH